Bayer AG - Product Pipeline Review - 2015 - Product Image

Bayer AG - Product Pipeline Review - 2015

  • ID: 3440592
  • Company Profile
  • 222 pages
  • Global Markets Direct
  • Bayer AG
1 of 4
Bayer AG - Product Pipeline Review - 2015

Summary

The report ‘Bayer AG - Product Pipeline Review - 2015’, provides an overview of the Bayer AG’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Bayer AG’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Bayer AG including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Bayer AG’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Bayer AG’s pipeline products

Reasons to buy

- Evaluate Bayer AG’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Bayer AG in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Bayer AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Bayer AG and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Bayer AG
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Bayer AG and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Bayer AG Snapshot

Bayer AG Overview

Key Information

Key Facts

Bayer AG - Research and Development Overview

Key Therapeutic Areas

Bayer AG - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Combination Treatment Modalities

Pipeline Products - Partnered Products

Pipeline Products - Out-Licensed Products

Bayer AG - Pipeline Products Glance

Bayer AG - Late Stage Pipeline Products

Bayer AG - Clinical Stage Pipeline Products

Bayer AG - Early Stage Pipeline Products

Bayer AG - Unknown Stage Pipeline Products

Bayer AG - Drug Profiles

aflibercept

BAY-818973

radium Ra 223 dichloride

rivaroxaban

(nifedipine + candesartan cilexetil)

amikacin sulfate

ciprofloxacin

copanlisib hydrochloride

damoctocog alfa pegol

dienogest

mapracorat

regorafenib

sorafenib tosylate

tedizolid phosphate

(anastrozole + levonorgestrel)

anetumab ravtansine

BAY-1067197

BAY-1142524

BAY-858501

finerenone

molidustat

refametinib

riociguat

roniciclib

vericiguat

vilaprisan

BAY sGCstim

BAY-1082439

BAY-1093884

BAY-1097761

BAY-1112054

BAY-1125976

BAY-1128688

BAY-1129980

BAY-1143269

BAY-1143572

BAY-1161909

BAY-1163877

BAY-1179470

BAY-1187982

BAY-1213790

BAY-1214784

BAY-1217389

BAY-1238097

Drug for Diabetic Foot Ulcer

Drug to Antagonize GnRH Receptor for Endometriosis and Uterine Leiomyoma

Monoclonal Antibodies for Cancer

Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis

Small Molecule to Inhibit Kinase for Inflammation and Cancer

Vaccine for Follicular Lymphoma

BAY sGCact

BAY-1001931

BAY-1024767

BAY-606583

Bay-846

BR-5489

Monoclonal Antibodies for Undisclosed Indication

Protein To Inhibit HER-2 Receptor for Breast Cancer

Protein to Inhibit PDGFR-Beta Receptor for Solid Tumors

Small Molecule to Inhibit Plasminogen for Rare Bleeding Disorder

Small Molecules to Inhibit Wnt Pathway for Cancer

ZK-191784

ZK-216348

Drugs for Endometriosis and Uterine Fibroids

Monoclonal Antibody Conjugated to Target CD22 for Hematological Cancers

Recombinant Protein for Solid Tumors

Small Molecule to Inhibit Epigenetic Target for Cancer

Small Molecules for Cancer

Immunotherapy for Cancer

Bayer AG - Pipeline Analysis

Bayer AG - Pipeline Products by Target

Bayer AG - Pipeline Products by Route of Administration

Bayer AG - Pipeline Products by Molecule Type

Bayer AG - Pipeline Products by Mechanism of Action

Bayer AG - Recent Pipeline Updates

Bayer AG - Dormant Projects

Bayer AG - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

Bayer AG - Company Statement

Bayer AG - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Bayer AG, Key Information

Bayer AG, Key Facts

Bayer AG - Pipeline by Indication, 2015

Bayer AG - Pipeline by Stage of Development, 2015

Bayer AG - Monotherapy Products in Pipeline, 2015

Bayer AG - Combination Treatment Modalities in Pipeline, 2015

Bayer AG - Partnered Products in Pipeline, 2015

Bayer AG - Partnered Products/ Combination Treatment Modalities, 2015

Bayer AG - Out-Licensed Products in Pipeline, 2015

Bayer AG - Out-Licensed Products/ Combination Treatment Modalities, 2015

Bayer AG - Pre-Registration, 2015

Bayer AG - Phase III, 2015

Bayer AG - Phase II, 2015

Bayer AG - Phase I, 2015

Bayer AG - Preclinical, 2015

Bayer AG - Discovery, 2015

Bayer AG - Unknown, 2015

Bayer AG - Pipeline by Target, 2015

Bayer AG - Pipeline by Route of Administration, 2015

Bayer AG - Pipeline by Molecule Type, 2015

Bayer AG - Pipeline Products by Mechanism of Action, 2015

Bayer AG - Recent Pipeline Updates, 2015

Bayer AG - Dormant Developmental Projects,2015

Bayer AG - Discontinued Pipeline Products, 2015

Bayer AG, Subsidiaries

List of Figures

Bayer AG - Pipeline by Top 10 Indication, 2015

Bayer AG - Pipeline by Stage of Development, 2015

Bayer AG - Monotherapy Products in Pipeline, 2015

Bayer AG - Combination Treatment Modalities in Pipeline, 2015

Bayer AG - Partnered Products in Pipeline, 2015

Bayer AG - Out-Licensed Products in Pipeline, 2015

Bayer AG - Pipeline by Top 10 Target, 2015

Bayer AG - Pipeline by Top 10 Route of Administration, 2015

Bayer AG - Pipeline by Top 10 Molecule Type, 2015

Bayer AG - Pipeline Products by Top 10 Mechanism of Action, 2015
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll